Clinical trials: Pharmacotherapy
Urinary Bladder Neoplasms
A Study of TAR-200 in Participants With Muscle-Invasive Urothelial Carcinoma of the Bladder Who Are Ineligible for or Refuse Cisplatin-based Chemotherapy and Who Are Unfit for Radical Cystectomy
The purpose of this study is to evaluate both the safety and tolerability of up to 4 dosing cycles of TAR-200 for 21 days per dosing cycle in the induction period.
- Trial name
- NCT03404791
- Testing
- TAR-200
- Where
- 12 sites in United States, Spain
- Volunteers
- 35 people
- Sponsor
- Janssen Research & Development, LLC
Thrombocytopenia, Neutropenia
Study of Drug to Reduce Thrombocytopenia in Patients Receiving Chemo for Ovarian, Fallopian Tube or Peritoneal Cancer
This research study will investigate the safety and effectiveness of two different dose levels of a new, unapproved drug to be given along with the chemotherapy regimens gemcitabine and carboplatin or gemcitabine and cisplatin…
- Conditions
- Thrombocytopenia, Neutropenia, Lymphopenia, Anemia
- Trial name
- NCT00771810
- Testing
- TXA127
- Where
- 6 sites in United States
- Volunteers
- 34 people
- Sponsor
- Tarix Pharmaceuticals
Chronic Obstructive Pulmonary Disease
Evaluation of Clinical Effectiveness of Roflumilast in Routine Practice, in Chronic Obstructive Pulmonary Disease (COPD) Patients in Greece
The purpose of this study was to examine the characteristics of patients selected for treatment with roflumilast and the effectiveness and safety of roflumilast in patients with severe or very severe COPD treated in Hospital and…
- Trial name
- ATLAS (NCT02187926)
- Volunteers
- 2,577 people
- Sponsor
- AstraZeneca
Nausea, Vomiting
Aprepitant for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) Associated With Highly Emetogenic Chemotherapy (0869-801)(COMPLETED)
A multicenter trial to assess the safety and efficacy of an investigational drug in the prevention of chemotherapy-induced nausea and vomiting (CINV) in patients with confirmed solid tumors who will be treated with a chemotherapy…
- Trial name
- NCT00090207
- Testing
- MK0869, aprepitant / Duration of Treatment: 3 days, Comparator: ondansetron / Duration of Treatment: 4 days
- Volunteers
- 477 people
- Sponsor
- Merck Sharp & Dohme LLC
Liver Cancer
Chemotherapy in Treating Patients With Liver Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Giving drugs in different ways may kill more tumor cells.
- Trial name
- NCT00003044
- Testing
- cisplatin-e therapeutic implant
- Where
- 3 sites in United States, Hong Kong
- Volunteers
- 55 people
- Sponsor
- Matrix Pharmaceutical
Short Bowel Syndrome
A Study of Teduglutide in Chinese Adults With Short Bowel Syndrome
The main aim of the study is to assess how well teduglutide works over 24 weeks in Chinese adult participants with short bowel syndrome (SBS) who need parenteral support and to see how much it can reduce the amount of parenteral…
- Trial name
- NCT06973304
- Testing
- Teduglutide
- Where
- 4 sites in China
- Volunteers
- 13 people
- Sponsor
- Takeda
DSF
Fluorouracil Implants Used for Intraperitoneal Chemotherapy During Operation for Treatment of Phase III Gastric Cancer.
SinoFuan is a kind of Fluorouracil Implants for intraperitoneal chemotherapy during operation for treatment of gastric cancer. The indication has bee approved by Chinese FDA. The study is a post-marketing study.
- Trial name
- NCT02269904
- Testing
- Fluorouracil Implants, Xelox regimes
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Jiangsu Simcere Pharmaceutical Co., Ltd.
Diabetes Mellitus
Efficacy of Pioglitazone on Macrovascular Outcome in Patients With Type 2 Diabetes
The purpose of this study is to determine whether pioglitazone, once daily (QD), can delay the time to death, heart attack, acute coronary syndrome, heart bypass surgery, stroke, leg bypass surgery or amputation in patients with…
- Trial name
- PROactive (NCT00174993)
- Testing
- Pioglitazone
- Where
- 19 sites in Austria, Belgium and 17 more
- Volunteers
- 4,373 people
- Sponsor
- Takeda
Chemotherapy-induced Neutropenia
Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer
The purpose of the present trial is to evaluate the safety, tolerability and pharmacokinetics(PK)/pharmacodynamics(PD) of single subcutaneous injection of GW003 in breast cancer patients.
- Trial name
- NCT02725606
- Testing
- Pegylated Recombinant Human G-CSF, GW003
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Jiangsu T-Mab Biopharma Co.,Ltd
Small Cell Lung Carcinoma
Study Of Irinotecan Hydrochloride (Campto(R)) And Cisplatin Versus Etoposide And Cisplatin In Small Cell Lung Cancer
To compare the effects of irinotecan hydrochloride with cisplatin to the "standard" regimen etoposide plus cisplatin on overall survival, in chemotherapy-naive patients with newly diagnosed Extensive Disease-Small Cell Lung…
- Trial name
- NCT00143455
- Testing
- Etoposide + cisplatin, Irinotecan + cisplatin
- Where
- 67 sites in Austria, Belgium and 11 more
- Volunteers
- 485 people
- Sponsor
- Pfizer
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of ponatinib or imatinib.
- Trial name
- NCT03589326
- Testing
- Ponatinib, Imatinib, Vincristine
- Where
- 92 sites in United States, Argentina and 18 more
- Volunteers
- 245 people
- Sponsor
- Takeda
Hypercholesterolemia
Efficacy of Lapaquistat Acetate and Atorvastatin on Blood Cholesterol Levels in Subjects With Primary Hypercholesterolemia
The purpose of this study is to determine the efficacy of lapaquistat acetate, once daily (QD), on lowering cholesterol in subjects already taking atorvastatin.
- Trial name
- NCT00143676
- Testing
- Lapaquistat acetate and atorvastatin, Atorvastatin
- Where
- 78 sites in United States
- Volunteers
- 448 people
- Sponsor
- Takeda
Head and Neck Neoplasms
Recombinant Human Endostatin Adenovirus Combined With Chemotherapy for Advanced Head and Neck Malignant Tumors
This study will investigate the efficacy and safety of recombinant human endostatin adenovirus combined with chemotherapy for advanced head and neck malignant tumors.
- Trial name
- NCT02283489
- Testing
- recombinant human endostatin adenovirus, Cisplatin injection, Paclitaxel injection
- Where
- 4 sites in China
- Volunteers
- 180 people
- Sponsor
- Renmiao Zhang
Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Women With Folate Receptor (FR) Alpha Positive Advanced Epithelial Ovarian Cancer (EOC), Primary Peritoneal or Fallopian Tube Cancer
This is a Phase 3, open label, randomized study designed to compare the safety and efficacy of mirvetuximab soravtansine to that of selected single-agent chemotherapy (Investigator's choice) in women with platinum-resistant…
- Conditions
- Epithelial Ovarian Cancer, Primary Peritoneal Carcinoma, Fallopian Tube Cancer, Ovarian Cancer
- Trial name
- FORWARD I (NCT02631876)
- Testing
- Mirvetuximab soravtansine, Paclitaxel, Pegylated liposomal doxorubicin
- Where
- 131 sites in United States, Belgium and 11 more
- Volunteers
- 366 people
- Sponsor
- ImmunoGen, Inc.
Leukemia, Myeloid, Acute
SGI-110 in Adults With Untreated Acute Myeloid Leukemia (AML), Not Considered Candidates for Intensive Remission Induction
To compare efficacy and safety between SGI-110 and Treatment Choice in adults with previously untreated AML who are not considered candidates for intensive remission induction chemotherapy.
- Trial name
- NCT02348489
- Testing
- SGI-110 (guadecitabine), Treatment Choice
- Where
- 135 sites in United States, Australia and 22 more
- Volunteers
- 815 people
- Sponsor
- Astex Pharmaceuticals, Inc.
Weight Regain Post Bariatric Surgery
Efficacy of Naltrexone HCl/Bupropion HCl Extended Release Versus Placebo for Treatment of Weight Regain in Participants Post Bariatric Surgery
The purpose of this study is to determine the effect of naltrexone hydrochloride(HCL) and bupropion hydrochloride extended release combination (NB) compared with placebo on weight loss in obese participants post bariatric surgery.
- Trial name
- NCT02616315
- Testing
- Naltrexone HCl/Bupropion HCl
- Where
- 2 sites in United States
- Sponsor
- Takeda
Non-Small Cell Lung Cancer (NSCLC)
A Study to Evaluate the Impact of Management Strategies on Gastrointestinal-Related Adverse Events in Participants With Non-Small Cell Lung Cancer Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations Receiving TAK-788
The purpose of the study is to characterize the incidence and severity of TAK-788-associated diarrhea in previously treated participants with locally advanced or metastatic non-small-cell lung cancer (NSCLC) whose tumors harbor…
- Trial name
- NCT04576208
- Testing
- TAK-788, Antidiarrheal prophylaxis
- Sponsor
- Takeda
Gastric Cancer, GastroEsophageal Cancer
Effect of Tumor Treating Fields (TTFields, 150 KHz) Concomitant with Chemotherapy As First Line Treatment of Unresectable Gastroesophageal Junction or Gastric Adenocarcinoma
The study is a prospective, single arm, phase II trial aimed to evaluate the efficacy and safety of Tumor Treating Fields (TTFields) concomitant with XELOX for the treatment of unresectable, locally advanced or metastatic…
- Trial name
- NCT04281576
- Testing
- NovoTTF-100L(P), Oxaliplatin, Capecitabine
- Where
- Hong Kong
- Volunteers
- 28 people
- Sponsor
- NovoCure Ltd.
Non-Small Cell Lung Cancer
A Phase III Study of the Efficacy of Taxotere/Aptosyn Versus Taxotere/Placebo in Non-Small Cell Lung Cancer Patients
Taxotere has been approved by the FDA and is considered a standard treatment for patients with lung cancer who have failed prior platinum-containing regimens.
- Trial name
- NCT00085826
- Testing
- Exisulind
- Where
- 114 sites in United States
- Volunteers
- 600 people
- Sponsor
- Astellas Pharma Inc
Non-Small Cell Lung Carcinoma
Study of Pembrolizumab (MK-3475) Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (MK-3475-024/KEYNOTE-024)
This is a study to assess the efficacy and safety of pembrolizumab (MK-3475/SCH 900475) compared to standard of care (SOC) platinum-based chemotherapies in the treatment of participants with previously untreated stage IV…
- Trial name
- NCT02142738
- Testing
- Pembrolizumab, Paclitaxel, Carboplatin
- Volunteers
- 305 people
- Sponsor
- Merck Sharp & Dohme LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.